|
Hereditary Sensory and Autonomic Neuropathies
|
0.520 |
GeneticVariation
|
group |
BEFREE |
Mutations in FAM134B associated with hereditary sensory and autonomic neuropathy type IIB (HSAN IIB).
|
29226326 |
2018 |
|
Hereditary Sensory and Autonomic Neuropathies
|
0.520 |
GeneticVariation
|
group |
BEFREE |
Assessment of the variants detected by mapped sequencing reads followed by Sanger confirmation revealed that the proband is a compound heterozygote for rare variants within RETREG1 (FAM134B), a gene associated with a recessive form of hereditary sensory and autonomic neuropathy, but not with epileptic encephalopathy or global developmental delay.
|
31475481 |
2019 |
|
Hereditary Sensory Autonomic Neuropathy, Type 2
|
0.410 |
GeneticVariation
|
disease |
BEFREE |
Although mutations in FAM134B and the HSN2 exon of WNK1 were associated with HSANII, the etiology of a substantial number of cases remains unexplained.
|
21820098 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of FAM134B was significantly associated with tumor size (P = 0.025), pathological vascular invasion (P = 0.026), differentiation grade (P = 0.023), cancer recurrence (P = 0.044), and portal vein tumor thrombus (P = 0.036) in HCC.
|
30556279 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of FAM134B mRNA and protein was present in 31.2% (n = 29/93) and 36.6% (n = 41/112), respectively, in tumors, whereas downregulation occurred in 39.8% (n = 37/93) and 63.4% (n = 71/112), respectively.
|
30794892 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In cancer, FAM134B acts as a tumor suppressor and inhibit cancer growth both in-vitro and in-vivo.
|
29226326 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent work has exhibited that FAM134B plays a pivotal role in autophagy-mediated turnover of endoplasmic reticulum (ER) membranes, tumor inhibition and lipid homeostasis.
|
31446166 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FAM134B is a putative tumour suppressor gene and no mutations in FAM134B have been reported in colorectal cancer (CRC) to date.
|
28144752 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In colorectal adenocarcinomas, lower levels of JK-1(FAM134B) protein expression were associated with younger age (p=0.032), larger tumour size (p=0.004), advanced cancer stages (p=0.016) and higher rates of cancer recurrence (p=0.04).
|
24973512 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The miR-186-5p expression promotes colorectal cancer pathogenesis by regulating tumour suppressor FAM134B.
|
28549913 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent work has shown that FAM134B plays a pivotal role in autophagy-mediated turnover of endoplasmic reticulum (ER) membranes, tumor inhibition and lipid homeostasis.
|
30291780 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Promoter hypermethylation inactivate tumor suppressor FAM134B and is associated with poor prognosis in colorectal cancer.
|
29318692 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Stage dependent expression and tumor suppressive function of FAM134B (JK1) in colon cancer.
|
27120410 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
FAM134B is an autophagy regulator of endoplasmic reticulum and acts as a cancer suppressor in colon cancer.
|
29964340 |
2018 |
|
Malignant Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
In addition, FAM134B mutations were associated with various clinical and pathological variables, including sex of the patients, presence of metachronous cancer, size, T staging, presence of distant metastases, and positivity of microsatellite instability (MSI) in the cancer (p < 0.05).
|
28144752 |
2017 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In cancer, FAM134B acts as a tumor suppressor and inhibit cancer growth both in-vitro and in-vivo.
|
29226326 |
2018 |
|
Malignant Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
This is the first study showing significant correlations of the JK-1 (FAM134B) gene copy number alterations with clinical and pathological features in a large cohort of pre-invasive and invasive colorectal malignancies.
|
24825067 |
2014 |
|
Malignant Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
FAM134B mutation is still unexplored in cancer.
|
27373372 |
2016 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
To conclude, expression analysis, in vitro and in vivo indicated that FAM134B acts as a cancer suppressor gene in colon cancer.
|
27120410 |
2017 |
|
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Our method has demonstrated good sensitivity (LOD = 1.0pM) and reproducibility (% RSD = <5%, for n = 3) for detecting FAM134B mRNA in two cancer cell lines and a small cohort of clinical samples (number of samples = 26) collected from patients with oesophageal cancer.
|
28688308 |
2017 |
|
Malignant tumor of colon
|
0.060 |
Biomarker
|
disease |
BEFREE |
JK1 (FAM134B) represses cell migration in colon cancer: a functional study of a novel gene.
|
24927874 |
2014 |
|
Malignant tumor of colon
|
0.060 |
Biomarker
|
disease |
BEFREE |
Herein, this study aims to determine the interacting partners of FAM134B for the first time in colon cancer and to explore the precise location of FAM134B in cancer signalling pathways.
|
29964340 |
2018 |
|
Malignant tumor of colon
|
0.060 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation-specific high-resolution melt-curve analysis followed by sequencing was used to identify FAM134B promoter methylation in colorectal adenomas (N = 32), colorectal adenocarcinomas (N = 164), matched adjacent non-neoplastic colorectal mucosae (N = 83) and colon cancer cell lines (N = 4).
|
29318692 |
2018 |
|
Malignant tumor of colon
|
0.060 |
Biomarker
|
disease |
BEFREE |
We found excellent sensitivity and specificity for the analysis of FAM134B protein in a panel of colon cancer cell lines and serum samples.
|
28273937 |
2017 |
|
Malignant tumor of colon
|
0.060 |
Biomarker
|
disease |
BEFREE |
To conclude, expression analysis, in vitro and in vivo indicated that FAM134B acts as a cancer suppressor gene in colon cancer.
|
27120410 |
2017 |